Nivolumab plus ipilimumab in the treatment of advanced melanoma

被引：38

作者：

Tsai, Katy K. ^{[1
]}

Daud, Adil I. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94115 USA

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2015年 / 8卷

关键词：

Melanoma; Immunotherapy; PD-1; CTLA-4; Nivolumab; Ipilimumab; T-CELLS; UNTREATED MELANOMA; CTLA-4; PD-1;

D O I：

10.1186/s13045-015-0219-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment outcomes. Combination immunotherapy, in particular combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade, represents an important first step in this direction.

引用

页数：4

共 50 条

[1] Nivolumab plus ipilimumab in the treatment of advanced melanoma
Katy K. Tsai
Adil I. Daud
Journal of Hematology & Oncology, 8
[2] Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, Jedd D.
Kluger, Harriet
Callahan, Margaret K.
Postow, Michael A.
Rizvi, Naiyer A.
Lesokhin, Alexander M.
Segal, Neil H.
Ariyan, Charlotte E.
Gordon, Ruth-Ann
Reed, Kathleen
Burke, Matthew M.
Caldwell, Anne
Kronenberg, Stephanie A.
Agunwamba, Blessing U.
Zhang, Xiaoling
Lowy, Israel
Inzunza, Hector David
Feely, William
Horak, Christine E.
Hong, Quan
Korman, Alan J.
Wigginton, Jon M.
Gupta, Ashok
Sznol, Mario
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02): : 122 - 133
[3] Nivolumab plus Ipilimumab in Advanced Melanoma
Santhosh, Akhil
NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (12): : 1245 - 1246
[4] Ipilimumab plus nivolumab for advanced melanoma
Hassel, Jessica C.
LANCET ONCOLOGY, 2016, 17 (11): : 1471 - 1472
[5] COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA
Tibet, B.
VALUE IN HEALTH, 2018, 21 : S45 - S45
[6] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST -LINE TREATMENT OF ADVANCED MELANOMA
Baker, T. M.
Paly, V. F.
Sabater, J.
Okoro, T.
Kotapati, S.
Briggs, A.
VALUE IN HEALTH, 2016, 19 (07) : A730 - A730
[7] Partial Remission of advanced Melanoma by Combination Therapy with Nivolumab and Trametinib after Treatment Failure with Ipilimumab plus Nivolumab
Zaremba, A.
Chorti, E.
Jockenhoefer, F.
Albrecht, M.
Placke, J. M.
Knispel, S.
Schadendorf, D.
Hadaschik, E.
Roesch, A.
Ugurel, S.
Zimmer, L.
Livingstone, E.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 38 - 38
[8] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Gonzalez, Rene
Grob, Jean-Jacques
Rutkowski, Piotr
Lao, Christopher D.
Cowey, C. Lance
Schadendorf, Dirk
Wagstaff, John
Dummer, Reinhard
Ferrucci, Pier Francesco
Smylie, Michael
Butler, Marcus O.
Hill, Andrew
Marquez-Rodas, Ivan
Haanen, John B. A. G.
Guidoboni, Massimo
Maio, Michele
Schoffski, Patrick
Carlino, Matteo S.
Lebbe, Celeste
McArthur, Grant
Ascierto, Paolo A.
Daniels, Gregory A.
Long, Georgina, V
Bas, Tuba
Ritchings, Corey
Larkin, James
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +
[9] PKPD relationship of ipilimumab plus nivolumab combination in patients with advanced melanoma
Goldwirt, L.
Louveau, B.
Liv, T.
Baroudjian, B.
Allayous, C.
Da Meda, L.
Delyon, J.
Sauvageon, H.
Lebbe, C.
Mourah, S.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 38 - 38
[10] Nivolumab and Ipilimumab in Advanced Melanoma Reply
Wolchok, Jedd D.
Rollin, Linda
Larkin, James
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25): : 2503 - 2504

← 1 2 3 4 5 →